pharmaand
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, pharmaand sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
pharmaand: 15 sponsored US clinical trials, none currently recruiting.
pharmaand sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 4 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fallopian Tube Cancer, with 2 trials.
Top-decile sponsor footprint
pharmaand ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
NCT04171700
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
NCT04179396
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
NCT04150289
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
NCT03824704
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
NCT03992131
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
NCT03397394
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
NCT02855944
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02952534
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
NCT02654990
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
NCT01968213
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
NCT02042378
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
NCT01891344
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
NCT01482715
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 7 |
| Phase 3 | 4 |
Therapeutic Areas
How the pharmaand early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 10 completed (67%).
Phase mix: 4 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Fallopian Tube Cancer (2 trials), 8 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
pharmaand: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
pharmaand sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this pharmaand page
15 registered trials is a research-attention snapshot, not an endorsement of pharmaand or any single study.
- None of pharmaand's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Fallopian Tube Cancer is the condition pharmaand studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fallopian Tube Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
pharmaand pipeline card: 15 registered trials from official public datasets.Report a data error.